Previous 10 | Next 10 |
NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 14,031,336 of its common shares at a price to the public of $3.75 per share. In addition, an...
NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares and pre-funded warrants to purchase its common shares. In connection with this...
Quick Take Passage Bio ( PASG ) intends to raise $126 million in an IPO of its common stock, per an amended registration statement . The company is advancing a pipeline of genetic treatment candidates for monogenic (single gene pair) central nervous system [CNS] conditions. PASG has yet...
Axovant Gene Therapies (NASDAQ: AXGT ): Q3 GAAP EPS of -$0.62 beats by $0.01 .' Cash and cash equivalents of $27.81M Press Release More news on: Axovant Gene Therapies Ltd., Earnings news and commentary, ,
NEW YORK and BASEL, Switzerland, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today provided financial results for its third fiscal quarter ended December 31, 2019. Fiscal Third Quarter Finan...
Quick Take Passage Bio ( PASG ) has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement . The firm is developing genetic treatments for monogenic (single gene) central nervous system [CNS] health conditions. PASG is at pre-clinical stage...
Adaptimmune Therapeutics PLC (NASDAQ: ADAP ) +56% as SPEAR T-cell platform delivers initial responses in four solid tumors. More news on: Adaptimmune Therapeutics plc, Verona Pharma plc, Mereo BioPharma Group plc, Stocks on the move, Read more ...
Thinly traded micro cap Axovant Gene Therapies (NASDAQ: AXGT ) perks up 9% premarket on light volume on the heels of its pipeline progress and expected 2020 milestones. Highlights: More news on: Axovant Gene Therapies Ltd., Healthcare stocks news, Stocks on the move, Read...
NEW YORK and BASEL, Switzerland, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced recent progress in its gene therapy programs, including a 12-month update o...
Thinly traded micro cap Axovant Gene Therapies (NASDAQ: AXGT ) is up 17% premarket on light volume in reaction to results from one child with GM1 gangliosidosis who received gene therapy candidate AXO-AAV-GM1. More news on: Axovant Gene Therapies Ltd., Healthcare stocks news,...
News, Short Squeeze, Breakout and More Instantly...
Axovant Gene Therapies Ltd. Company Name:
AXGT Stock Symbol:
NYSE Market:
On-track to report t opline r esults from low-dose cohort by end of 2020 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to ra...
A pioneering researcher , Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapy Dr. Gao recently served as President of the American Society for Gene and Cell Therapy (ASGCT) and has been ranked as one of...
Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicines Company’s common stock will trade on the NASDAQ under new ticker “SIOX” effective November 13, 2020 ...